The results suggest that PKRAs have the potential to be effective and disease-modifying therapies for PK deficiency, offering early and robust Hb responses and the normalization of Hb levels in a significant proportion of patients. Here, GSTM1 is linked to pyruvate kinase deficiency of red cells.